Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

Leukemia. 2022 Dec;36(12):2917-2921. doi: 10.1038/s41375-022-01691-1. Epub 2022 Sep 16.
No abstract available

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Autografts
  • Dexamethasone / therapeutic use
  • Humans
  • Lenalidomide / therapeutic use
  • Multiple Myeloma* / diagnosis
  • Multiple Myeloma* / drug therapy
  • Transplantation, Autologous

Substances

  • Dexamethasone
  • ixazomib
  • Lenalidomide